BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 32437708)

  • 1. Modelling cognitive deficits in Parkinson's disease: Is CA2 a gateway for hippocampal synucleinopathy?
    Cinar E; Yalcin-Cakmakli G; Saka E; Ulusoy A; Yuruker S; Elibol B; Tel BC
    Exp Neurol; 2020 Aug; 330():113357. PubMed ID: 32437708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons.
    Caudal D; Alvarsson A; Björklund A; Svenningsson P
    Exp Neurol; 2015 Nov; 273():243-52. PubMed ID: 26363495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease.
    Febbraro F; Sahin G; Farran A; Soares S; Jensen PH; Kirik D; Romero-Ramos M
    Neurobiol Dis; 2013 Aug; 56():47-58. PubMed ID: 23567651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling Parkinson's disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain.
    Thakur P; Breger LS; Lundblad M; Wan OW; Mattsson B; Luk KC; Lee VMY; Trojanowski JQ; Björklund A
    Proc Natl Acad Sci U S A; 2017 Sep; 114(39):E8284-E8293. PubMed ID: 28900002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hippocampal CA2 Lewy pathology is associated with cholinergic degeneration in Parkinson's disease with cognitive decline.
    Liu AKL; Chau TW; Lim EJ; Ahmed I; Chang RC; Kalaitzakis ME; Graeber MB; Gentleman SM; Pearce RKB
    Acta Neuropathol Commun; 2019 Apr; 7(1):61. PubMed ID: 31023342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
    Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
    Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
    Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
    Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hippocampal synaptic failure is an early event in experimental parkinsonism with subtle cognitive deficit.
    Belloso-Iguerategui A; Zamarbide M; Merino-Galan L; Rodríguez-Chinchilla T; Gago B; Santamaria E; Fernández-Irigoyen J; Cotman CW; Prieto GA; Quiroga-Varela A; Rodríguez-Oroz MC
    Brain; 2023 Dec; 146(12):4949-4963. PubMed ID: 37403195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.
    Duffy MF; Collier TJ; Patterson JR; Kemp CJ; Luk KC; Tansey MG; Paumier KL; Kanaan NM; Fischer DL; Polinski NK; Barth OL; Howe JW; Vaikath NN; Majbour NK; El-Agnaf OMA; Sortwell CE
    J Neuroinflammation; 2018 May; 15(1):129. PubMed ID: 29716614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emotional memory impairments induced by AAV-mediated overexpression of human α-synuclein in dopaminergic neurons of the ventral tegmental area.
    Alvarsson A; Caudal D; Björklund A; Svenningsson P
    Behav Brain Res; 2016 Jan; 296():129-133. PubMed ID: 26341317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC α-synuclein transgenic rat model of Parkinson's disease.
    Kohl Z; Ben Abdallah N; Vogelgsang J; Tischer L; Deusser J; Amato D; Anderson S; Müller CP; Riess O; Masliah E; Nuber S; Winkler J
    Neurobiol Dis; 2016 Jan; 85():206-217. PubMed ID: 26523794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
    Coune PG; Bensadoun JC; Aebischer P; Schneider BL
    J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease.
    Galiano-Landeira J; Torra A; Vila M; Bové J
    Brain; 2020 Dec; 143(12):3717-3733. PubMed ID: 33118032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Intranigral Infusion of Human-Alpha Synuclein Oligomers Induces a Cognitive Impairment in Rats Associated with Changes in Neuronal Firing and Neuroinflammation in the Anterior Cingulate Cortex.
    Palmas MF; Etzi M; Pisanu A; Camoglio C; Sagheddu C; Santoni M; Manchinu MF; Pala M; Fusco G; De Simone A; Picci L; Mulas G; Spiga S; Scherma M; Fadda P; Pistis M; Simola N; Carboni E; Carta AR
    Cells; 2022 Aug; 11(17):. PubMed ID: 36078036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
    Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
    Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
    Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
    J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease.
    Albert K; Voutilainen MH; Domanskyi A; Piepponen TP; Ahola S; Tuominen RK; Richie C; Harvey BK; Airavaara M
    J Neurosci Res; 2019 Mar; 97(3):346-361. PubMed ID: 30548446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.